Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Aqueous Afamelanotide Solution Stroke Study
2022-500919-40-01Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Oct 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in brain infarction, sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Safety of afamelanotide by monitoring and recording treatment-emergent adverse events (TEAEs). Started Oct 2024; status: completed.
02
Drugs
Afamelanotide
03
Conditions
brain infarction
Beyond the preview
Go deeper on 2022-500919-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500919-40-01.